U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products Guidance for Industry
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products Guidance for Industry October 2020

Download the Final Guidance Document Read the Federal Register Notice
Final
Docket Number:
FDA-2018-D-2583
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This guidance provides sponsors with recommendations on the nonclinical information to support development and approval of orally inhaled nicotine-containing drug products, including electronic nicotine delivery systems intended for smoking cessation and related chronic indications.

This guidance focuses on novel chemicals of the drug product formulation, novel chemicals generated from any chemical of the drug product formulation by the delivery system (e.g., heat-generated chemicals), and novel impurities from the drug product formulation and delivery system. This guidance does not address nonclinical toxicity studies that may be requested by the Center for Devices and Radiological Health to support use of the delivery system (e.g., biocompatibility studies).

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2018-D-2583.

 
Back to Top